MarketBeat
18 May 2026, 05:10 UTC · 3w ago
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
18 May 2026, 05:10 UTC · 3w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
6 claims · each scored for market impact
Incyte estimates it can convert about 20% of Jakafi immediate-release use to the newly approved once-daily Jakafi XR, representing about $750 million in sales. — A clear $750M revenue bridge significantly mitigates investor concern over Jakafi's upcoming loss of exclusivity and extends the franchise's commercial tail.
+0.80Incyte's core post-Jakafi business, including MONJUVI, ZYNYZ, and povorcitinib, is expected to reach at least a $3 billion to $4 billion run rate growing at roughly a 20% CAGR. — Quantifying a multi-billion dollar baseline for the post-Jakafi portfolio provides substantial downside protection and validates the long-term growth thesis for the stock.
+0.75International OPZELURA is expected to receive an atopic dermatitis indication in the second half of 2026, which could add $200 million to $300 million in incremental sales. — Entering a market five times larger than vitiligo in major ex-U.S. regions meaningfully expands OPZELURA's total addressable market and future revenue ceiling.
+0.60Continue reading
6 related stories
Top 1 mover · tap to explore
A 10% share of the frontline DLBCL market for MONJUVI would double the size of that franchise, with pivotal data to be shared at ASCO. — Doubling a commercial drug's revenue via a label expansion into frontline therapy represents a major upside catalyst contingent on upcoming clinical data.
+0.55Which stocks this story touches
The CEO provided a positive outlook on growth profiles, strong sales for Jakafi and OPZELURA, and a robust late-stage pipeline.
The company is mentioned only as the host of the conference where the CEO spoke.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
13h ago
